Skip to main content
OpenTrials
Completed

NCT Number: NCT02507167

Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8

The purpose of this study is to evaluate the impact of genetic variants of OATP 1B3 or MRP 2 on the systemic disposition of endogenously formed CCK-8 and to determine the influence of a single-dose of the transporter inhibitor rifampin (600 mg) on the systemic disposition of endogenously formed CCK-8. Endogenous CCK-8 secretion will be induced by a single-dose standardized liquid mixed meal.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastrointestinal Hormones

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Department of Clinical Pharmacology

Greifswald, 17489, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age: 18-45 years
  • sex: male
  • 12 subjects being homozygote wild-type carriers of OATP 1B3 (c.SLCO 1B3 699 AA and c.SLCO 1B3 334 GG) and MRP 2
  • 12 subjects being homozygotes of the MRP 2 variants (genetic loss of function) and homozygote wild-type carriers of OATP 1B3
  • 12 subjects being homozygotes of the OATP 1B3 variants (c.SLCO 1B3 699 GG and c.SLCO 1B3 334 TT) and homozygotes wild-type carriers of MRP 2
  • BMI: ≥ 19 kg/m2 and ≤ 27 kg/m2
  • good health as evidenced by the results of the clinical examination, ECG, and the laboratory check-up, which will be judged by the clinical investigator not to differ in a clinical relevant way from the healthy state
  • written informed consent given by the volunteer after being provided with detailed information (both, verbally and written) about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the drug

Exclusion criteria

  • hepatic and renal diseases and/or pathological findings, which might interfere with pharmacokinetics and pharmacodynamics of the study medication
  • gastrointestinal diseases and/or pathological findings (e.g. stenoses), which might interfere with pharmacokinetics and pharmacodynamics of the study medication
  • subjects with existing dysfunction in regulation of glucose metabolism, e.g. deficiency of glucose-6-phosphate dehydrogenase (Glc-6-P DHG) and/ or pathological findings
  • subjects with alcohol and/ or drug dependence and a alcohol consumption more than 20 g alcohol/ day
  • excessive smoking (more than 10 cigarettes or equivalents/ day)
  • subjects with positive finding of HBsAG, HIV and/ or drugs
  • subjects being on a diet (inclusive special or uniform nutritional habits, e.g. vegetarians or undercaloric diet)
  • strong coffee and/ or tea consumption (≥ 1 liter a day)
  • subjects suspected or known not to follow instructions
  • subjects who are unable to understand written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
  • subjects liable to orthostatic dysregulation, fainting, or blackout
  • subjects who took part in other clinical trials in the last 3 months (blocking time due to another clinical trial with investigational products)
  • acute illness less than 14 d in the past
  • blood donation within the last 3 months
  • any medication within 4 weeks prior to the intended first administration of the study medication which might influence functions of the gastrointestinal tract (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists, proton pump inhibitors, anticholinergics)
  • any other medication within 2 weeks prior to the first administration of the study medication or less than 10-time the half-live of the respective drug
  • intake of grapefruit containing food or beverages and poppy seeds containing products 14 d prior to the first drug administration until the last blood sampling of the study

Treatment and study plan

mixed meal

Dietary Supplement

250 ml Fortimel compact (chocolate)

Rifampin

Drug

oral rifampin administration (600 mg EREMFAT®)

Primary outcomes

  1. CCK-8

    Time frame: 3 h 15 min up to 2 h 15 min before and 5, 10, 15, 20, 25, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4 h after mixed meal

    Cholecystokinin amino acid 8 concentration in blood plasma

Secondary outcomes

  1. GLP-1

    Time frame: 3 h 15 min up to 2 h 15 min before and 5, 10, 15, 20, 25, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4 h after mixed meal

    Glucagon-like peptide-1 concentration in blood plasma

  2. GIP

    Time frame: 3 h 15 min up to 2 h 15 min before and 5, 10, 15, 20, 25, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4 h after mixed meal

    Gastric inhibitory polypeptide concentration in blood plasma

  3. glucagon

    Time frame: 3 h 15 min up to 2 h 15 min before and 5, 10, 15, 20, 25, 30, 45 min, 1, 1.25, 1.5, 2, 3, 4 h after mixed meal

    glucagon concentration in blood plasma

  4. glucose

    Time frame: 3 h 15 min up to 2 h 15 min before and 15, 30, 45 min, 1, 1.25 h after mixed meal

    glucose concentration in blood plasma

  5. potassium

    Time frame: 3 h 15 min up to 2 h 15 min before and 15, 30, 45 min, 1, 1.25 h after mixed meal

    potassium concentration in blood plasma

  6. C-peptide

    Time frame: 3 h 15 min up to 2 h 15 min before and 15, 30, 45 min, 1, 1.25 h after mixed meal

    connecting peptide concentration in blood plasma

  7. insulin

    Time frame: 3 h 15 min up to 2 h 15 min before and 15, 30, 45 min, 1, 1.25 h after mixed meal

    insulin concentration in blood plasma

Other outcomes

  1. area under the curve AUC from zero to the last sampling time above the limit of quantitation (AUC0-t) of rifampin and DAc-RIF (25-O-desacetyl-rifampin)

    Time frame: 3 h 15 min up to 2 h 15 min, 1.5, 1 h before and 5 min, 1, 2, 3, 4, 6, 8, 10 and 14 h after mixed meal

  2. area under the curve AUC from zero to 4 h (AUC0-4h) of rifampin and DAc-RIF (25-O-desacetyl-rifampin)

    Time frame: 3 h 15 min up to 2 h 15 min, 1.5, 1 h before and 5 min, 1, 2 h after mixed meal

  3. maximal concentration (Cmax) of rifampin and DAc-RIF (25-O-desacetyl-rifampin)

    Time frame: 3 h 15 min up to 2 h 15 min, 1.5, 1 h before and 5 min, 1, 2, 3, 4, 6, 8, 10 and 14 h after mixed meal

  4. time point of maximal concentration (tmax) of rifampin and DAc-RIF (25-O-desacetyl-rifampin)

    Time frame: 3 h 15 min up to 2 h 15 min, 1.5, 1 h before and 5 min, 1, 2, 3, 4, 6, 8, 10 and 14 h after mixed meal

  5. terminal half-life (t1/2) of rifampin and DAc-RIF (25-O-desacetyl-rifampin)

    Time frame: 3 h 15 min up to 2 h 15 min, 1.5, 1 h before and 5 min, 1, 2, 3, 4, 6, 8, 10 and 14 h after mixed meal

Sponsors and collaborators

Lead sponsor

University Medicine Greifswald

Other

Registry information

Official study title

Impact of Two Genetic Variants of OATP 1B3 or MRP 2 or Rifampin Mediated Transporter Inhibition on Systemic Disposition and Biological Efficacy of CCK-8 in 36 Healthy Male Individuals

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Jul 23, 2015
Registry last updated
Jul 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.